Signature Equity Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Signature Equity Partners's BMY Position: Q2 2026 in Review
Signature Equity Partners reduced its Bristol-Myers Squibb (BMY) stake by 58% in Q2 2026, selling an estimated $167K and leaving 2,134 shares worth $123K. The position accounts for 0.06% of the portfolio, ranked #257.
Signature Equity Partners first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $306K in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Signature Equity Partners held 2,134 shares of Bristol-Myers Squibb worth $123K as of Q2 2026.
- Signature Equity Partners sold 2,905 Bristol-Myers Squibb shares in Q2 2026, an estimated $167K.
- Bristol-Myers Squibb made up 0.06% of Signature Equity Partners's portfolio in Q2 2026, its #257 holding.
- Signature Equity Partners first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
- Signature Equity Partners's Bristol-Myers Squibb position peaked at $306K in Q1 2026.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.